Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Struthers

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Bioorganic & Medicinal Chemistry Letters|January 17, 2017
Investigation of piperazine benzamides as human β<sub>3</sub> adrenergic receptor agonists for the treatment of overactive bladderBart H Harper, Liping Wang, Cheng Zhu, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2015
Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of AutoimmunityPaul R Mangan, Linhui Julie Su, Victoria Jenny, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonistsGregori J Morriello, Harvey R Wendt, Alka Bansal, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant HypertensionWhitney L Petrilli, Scott B Hoyt, Clare London, et al.
Journal of Medicinal Chemistry|January 21, 2014
Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladderChristopher R Moyes, Richard Berger, Stephen D Goble, et al.
Mabs|July 8, 2025
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studiesFrank R Brennan, J Ryan Polli, Jean Sathish, et al.
Journal of Medicinal Chemistry|December 29, 2015
Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive BladderScott D Edmondson, Cheng Zhu, Nam Fung Kar, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus MonkeysScott B Hoyt, Whitney Petrilli, Clare London, et al.
Journal of Medicinal Chemistry|April 3, 2026
Discovery of Non-prostanoid EP4 Agonists for the Treatment of Inflammatory Bowel DiseaseHeidi L Perez, Sunita Dewnani, Steven A Spronk, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus MonkeysScott B Hoyt, Min K Park, Clare London, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Bioorganic & Medicinal Chemistry Letters|January 17, 2017
Investigation of piperazine benzamides as human β<sub>3</sub> adrenergic receptor agonists for the treatment of overactive bladderBart H Harper, Liping Wang, Cheng Zhu, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2015
Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of AutoimmunityPaul R Mangan, Linhui Julie Su, Victoria Jenny, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonistsGregori J Morriello, Harvey R Wendt, Alka Bansal, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant HypertensionWhitney L Petrilli, Scott B Hoyt, Clare London, et al.
Journal of Medicinal Chemistry|January 21, 2014
Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladderChristopher R Moyes, Richard Berger, Stephen D Goble, et al.
Mabs|July 8, 2025
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studiesFrank R Brennan, J Ryan Polli, Jean Sathish, et al.
Journal of Medicinal Chemistry|December 29, 2015
Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive BladderScott D Edmondson, Cheng Zhu, Nam Fung Kar, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus MonkeysScott B Hoyt, Whitney Petrilli, Clare London, et al.
Journal of Medicinal Chemistry|April 3, 2026
Discovery of Non-prostanoid EP4 Agonists for the Treatment of Inflammatory Bowel DiseaseHeidi L Perez, Sunita Dewnani, Steven A Spronk, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus MonkeysScott B Hoyt, Min K Park, Clare London, et al.
Pageof 3